期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
慢性乙型肝炎患者丙氨酸氨基转移酶正常值上限下调必要性初步探讨 被引量:3
1
作者 涂文辉 朱伟君 +2 位作者 钱峰 张继明 朱传武 《世界华人消化杂志》 CAS 2018年第30期1765-1771,共7页
目的初步探讨慢性乙型肝炎(hepatitis B virus, HBV)患者目前采用的丙氨酸氨基转移酶正常值上限(upper limit of normal, ULN)下调的必要性.方法收集非活动性乙肝表面抗原(hepatitisBsurface antigen,HBsAg)携带者及接受抗病毒治疗慢性... 目的初步探讨慢性乙型肝炎(hepatitis B virus, HBV)患者目前采用的丙氨酸氨基转移酶正常值上限(upper limit of normal, ULN)下调的必要性.方法收集非活动性乙肝表面抗原(hepatitisBsurface antigen,HBsAg)携带者及接受抗病毒治疗慢性HBV患者715例,病毒DNA均低于检测值下限,其中非活动性HBsAg携带者组57例(携带组),慢性HBV抗病毒治疗组455例(肝炎组), ALT低于2 ULN经肝穿活检后抗病毒治疗组203例(其中ALT<1 ULN 133例, ALT1-2ULN70例)(肝穿组).收集患者年龄、性别、体重、肝功能、血糖、血脂、血常规、乙肝病毒感染血清学标志物、乙肝病毒DNA定量、甲胎蛋白、肝胆脾B超等相关数据.肝穿组收集肝组织炎症分级、纤维化分期及抗病毒治疗1年后肝功能数据.结果全部患者(n=715)ALT水平中位数为19 IU/L, 95%百分位数为31.2 IU/L(95%CI:30-34 IU/L), 95%百分位数男性为34 IU/L(95%CI:31-35 IU/L),女性为26.2 IU/L(95%CI:25-30IU/L).肝穿组患者抗病毒治疗后ALT值下降显著,中位数由37 IU/L降至23 IU/L,具显著统计学差异(F=111.497, P=0.000).根据4种不同ALT正常值上限,肝脏显著炎症(≥G2)的检出率分别为0,38.78%,63.27%和84.69%.以ROC分析ALT对肝组织学显著炎症的评估价值, AUC值(Az)为0.751,对ALT与肝组织学炎症程度作Logistic回归分析, P值为0.331.结论目前应用的ALT正常值上限对评估慢性HBV是偏高的,似乎存在下调的必要性. 展开更多
关键词 乙型肝炎 慢性 组织学 炎症 丙氨酸氨基转移酶 正常值上限 下调
下载PDF
Precore/basal core promoter mutants quantification throughout phases of hepatitis B virus infection by Simpleprobe 被引量:8
2
作者 wen-hui tu Ying Lv +8 位作者 Yong-Mei Zhang Wei Hou Jin-Yu Wang Yi-Jun Zhang Hong-Yan Liu Hao-Xiang Zhu Yan-Li Qin Ri-Cheng Mao Ji-Ming Zhang 《World Journal of Gastroenterology》 SCIE CAS 2015年第21期6639-6648,共10页
AIM:To investigate precore/basal core promoter(PC/BCP) mutants throughout hepatitis B virus(HBV) infection and to determine their relationship to hepatitis B early antigen(HBeA g) titers.METHODS:We enrolled 191 patien... AIM:To investigate precore/basal core promoter(PC/BCP) mutants throughout hepatitis B virus(HBV) infection and to determine their relationship to hepatitis B early antigen(HBeA g) titers.METHODS:We enrolled 191 patients in various stages of HBV infection at the Huashan Hospital and the Taizhou Municipal Hospital from 2010 to 2012.None of the patients received antiviral therapy.HBV DNA from serum,was quantified by real-time PCR.The HBV genotype was determined by direct sequencing of the S gene.We used the Simpleprobe ultrasensitivequantitative method to detect PC/BCP mutants in each patient.We compared the strain number,percentage,and the changes in PC/BCP mutants in different phases,and analyzed the relationship between PC/BCP mutants and HBe Ag by multiple linear regression and logistic regression.RESULTS:Patients with HBV infection(n = 191) were assigned to groups by phase:Immune tolerance(IT) = 55,Immune clearance(IC) = 67,Low-replicative(LR) = 49,and HBeA g-negative hepatitis(ENH) = 20.Of the patients(male,112; female,79) enrolled,122 were HBe Ag-positive and 69 were HBe Ag-negative.The median age was 33 years(range:18-78 years).PC and BCP mutation detection rates were 84.82%(162/191) and 96.86%(185/191),respectively.In five HBe Ag-negative cases,we detected double mutation G1896A/G1899 A.The logarithm value of PC mutant quantities(log10 PC) significantly differed in IT,IC,and LR phases,as well as in the ENH phase(F = 49.350,P < 0.001).The logarithm value of BCP mutant quantities(log10 BCP) also differed during the four phases(F = 25.530,P < 0.001).Log10 PC and log10 BCP values were high in the IT and IC phases,decreased in the LR phase,and increased in the ENH phase,although the absolute value at this point remained lower than that in the IT and IC phases.PC mutant quantity per total viral load(PC%) and BCP mutant quantity per total viral load(BCP%) differed between phases(F = 20.040,P < 0.001; F = 10.830,P < 0.001),with PC% and BCP% gradually increasing in successive phases.HBeA g titers negatively correlated with PC%(Spearman's rho =-0.354,P < 0.001) and BCP%(Spearman's rho =-0.395,P < 0.001).The negative correlation between PC% and HBeA g status was significant(B =-5.281,P = 0.001),but there was no such correlation between BCP% and HBeA g status(B =-0.523,P = 0.552).CONCLUSION:PC/BCP mutants become predominant in a dynamic and continuous process.Log10 PC,log10 BCP,PC% and BCP% might be combined to evaluate disease progression.PC% determines HBeA g status. 展开更多
关键词 PRECORE mutant BASAL core promotermutant HEPATITIS B virus Quantification HEPATITIS Bearly ANTIGEN titers
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部